BC Week In Review | Jul 25, 2011
Company News

mtm, Roche deal

Roche will acquire cervical cancer diagnostic company mtm for about €130 million ($182.6 million) in cash and up to an additional €60 million ($84 million) in milestones. mtm will become part of Roche's tissue diagnostic...
BC Extra | Jul 20, 2011
Company News

Roche to acquire mtm

Roche (SIX:ROG; OTCQX:RHHBY) will acquire cervical cancer diagnostic company mtm laboratories AG (Heidelberg, Germany) for about EUR 130 million ($182.6 million) in cash and up to an additional EUR 60 million ($84 million) in milestones....
BC Week In Review | Apr 4, 2011
Clinical News

CINtec PLUS Cytology Kit: Pilot trial data

A prospective, German pilot trial analyzing cervical cytology specimens from 425 women ages 30 and up who tested negative for Pap abnormalities but positive for HPV showed that mtm's CINtec PLUS cervical cancer screening test...
BC Week In Review | May 24, 2010
Clinical News

CINtec PLUS cervical cancer screening test: Data

A retrospective analysis of 362 cases of atypical squamous cells of undetermined significance (ASC-US) and 415 cases of low-grade squamous intraepithelial lesions (LSIL) showed that mtm's CINtec PLUS cervical cancer screening test detected high-grade cervical...
BC Week In Review | Mar 29, 2010
Clinical News

CINtec PLUS cervical cancer screening test: Pilot trial data

Data from a prospective pilot study analyzing 661 abnormal Pap cervical cytology specimens showed that mtm's CINtec PLUS cervical cancer screening test had 87% sensitivity and 89.8% specificity for cervical intraepithelial neoplasia grade 2+ (CIN2+),...
BC Week In Review | Mar 15, 2010
Company News

mtm sales and marketing update

mtm launched its CINtec PLUS cervical cancer screening test in Europe to detect pre-cancerous cervical lesions. The immunocytochemistry assay simultaneously detects the cyclin dependent kinase inhibitor 2A ( CDKN2A ; INK4a ; ARF; p16INK4a ) biomarker and...
Items per page:
1 - 6 of 6